Page 22 - Bladder Dysfunction in the Context of the Bladder-Brain Connection - Ilse Groenendijk.pdf

20 Chapter 1
21. Noordhoff, T. C., Scheepe, J. R., t Hoen, L. A. et al. The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-15): Validation of the Dutch version in patients with multiple sclerosis and spinal cord injury. Neurourol Urodyn, 2867, 2018
22. Utomo, E., Korfage, I. J., Wildhagen, M. F. et al. Validation of the Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) in a Dutch population. Neurourol Urodyn, 24, 2015
23. Reuvers, S. H. M., Korfage, I. J., Scheepe, J. R. et al. The urinary-specific quality of life of multiple sclerosis patients: Dutch translation and validation of the SF-Qualiveen. Neurourol Urodyn, 1629, 2017
24. Reuvers, S. H. M., Korfage, I. J., Scheepe, J. R. et al. The validation of the Dutch SF-Qualiveen, a questionnaire on urinary-specific quality of life, in spinal cord injury patients. BMC Urol, 88, 2017
25. t Hoen, L. A., Korfage, I. J., Verhallen, J. T. et al. Vancouver Symptom Score for Dysfunctional Elimi-
nation Syndrome: Reliability and Validity of the Dutch Version. J Urol, 536, 2016
26. t Hoen, L. A., Utomo, E., Schouten, W. R. et al. The fecal incontinence quality of life scale (FIQL) and fecal incontinence severity index (FISI): Validation of the Dutch versions. Neurourol Urodyn, 710,
2017
27. t Hoen, L. A., Utomo, E., Steensma, A. B. et al. The Pelvic Organ Prolapse/Urinary Incontinence
Sexual Questionnaire (PISQ-12): validation of the Dutch version. Int Urogynecol J, 1293, 2015
28. Utomo, E., Blok, B. F., Pastoor, H. et al. The measurement properties of the five-item International
Index of Erectile Function (IIEF-5): a Dutch validation study. Andrology, 1154, 2015
29. Utomo, E., Blok, B. F., Steensma, A. B. et al. Validation of the Pelvic Floor Distress Inventory (PFDI- 20) and Pelvic Floor Impact Questionnaire (PFIQ-7) in a Dutch population. Int Urogynecol J, 531,
2014
30. Fox, P. T., Mintun, M. A. Noninvasive functional brain mapping by change-distribution analysis of
averaged PET images of H215O tissue activity. J Nucl Med, 141, 1989
31. Novelline, R. A. Squire’s Fundamentals of Radiology, Sixth edition ed. Harvard University Press,
2004
32. van der Zwaag, W., Francis, S., Head, K. et al. fMRI at 1.5, 3 and 7 T: characterising BOLD signal
changes. Neuroimage, 1425, 2009
33. Buckhard, F., Biosch, J., Cruz, F. et al. EAU Guidelines on Urinary Incontinence in Adults, 2019
34. Gravas, S., Cornu, J. N., Gacci, M. et al. EAU guidelines on Management of Non-Neurogenic Male
Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). 2019
35. Borello-France, D., Burgio, K. L., Goode, P. S. et al. Adherence to behavioral interventions for urge incontinence when combined with drug therapy: adherence rates, barriers, and predictors. Phys
Ther, 1493, 2010
36. Dumoulin, C., Hay-Smith, J., Frawley, H. et al. 2014 consensus statement on improving pelvic floor
muscle training adherence: International Continence Society 2011 State-of-the-Science Seminar.
Neurourol Urodyn, 600, 2015
37. Chapple, C. R., Khullar, V., Gabriel, Z. et al. The effects of antimuscarinic treatments in overactive
bladder: an update of a systematic review and meta-analysis. Eur Urol, 543, 2008
38. Rai, B. P., Cody, J. D., Alhasso, A. et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev, CD003193,
2012
39. Chapple, C. R., Kaplan, S. A., Mitcheson, D. et al. Randomized double-blind, active-controlled
phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol, 296, 2013